Evaxion Biotech A/S
Research Evaxion Biotech A/S (EVAX) on Bullrun: market cap USD 25.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEVAX
- ExchangeNASDAQ
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 25.60M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.73M
Valuation Snapshot
latest market cap is USD 25.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 7.53M | -USD 7.71M | -USD 6.64M | n/a | -1 | USD 23.23M | USD 7.50M | USD 17.04M |
| FY2024 | USD 3.34M | -USD 10.57M | -USD 12.94M | n/a | -10 | USD 5.95M | USD 10.10M | -USD 1.65M |
| FY2023 | USD 73.00K | -USD 22.13M | -USD 17.78M | n/a | -40.5 | USD 4.18M | USD 10.87M | -USD 4.73M |
| FY2022 | USD 0 | -USD 23.17M | -USD 26.07M | n/a | -49 | USD 13.18M | USD 10.26M | USD 8.30M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 25.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 39.78M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.92M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 26.00M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 42.84M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 102.57M | n/a | n/a | n/a |
About Evaxion Biotech A/S
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Evaxion Biotech A/S's market cap?
Evaxion Biotech A/S's market capitalization is USD 25.60M.
What does Evaxion Biotech A/S do?
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S.